1. Home
  2. INTS vs PHH Comparison

INTS vs PHH Comparison

Compare INTS & PHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • PHH
  • Stock Information
  • Founded
  • INTS 2012
  • PHH 2016
  • Country
  • INTS United States
  • PHH China
  • Employees
  • INTS N/A
  • PHH N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • PHH Package Goods/Cosmetics
  • Sector
  • INTS Health Care
  • PHH Consumer Discretionary
  • Exchange
  • INTS Nasdaq
  • PHH Nasdaq
  • Market Cap
  • INTS 10.9M
  • PHH 12.3M
  • IPO Year
  • INTS 2023
  • PHH 2024
  • Fundamental
  • Price
  • INTS $0.24
  • PHH $0.49
  • Analyst Decision
  • INTS Strong Buy
  • PHH
  • Analyst Count
  • INTS 4
  • PHH 0
  • Target Price
  • INTS $4.50
  • PHH N/A
  • AVG Volume (30 Days)
  • INTS 3.9M
  • PHH 1.1M
  • Earning Date
  • INTS 11-12-2025
  • PHH 08-03-2018
  • Dividend Yield
  • INTS N/A
  • PHH N/A
  • EPS Growth
  • INTS N/A
  • PHH N/A
  • EPS
  • INTS N/A
  • PHH N/A
  • Revenue
  • INTS N/A
  • PHH $2,768,120.00
  • Revenue This Year
  • INTS N/A
  • PHH N/A
  • Revenue Next Year
  • INTS N/A
  • PHH N/A
  • P/E Ratio
  • INTS N/A
  • PHH N/A
  • Revenue Growth
  • INTS N/A
  • PHH 42.65
  • 52 Week Low
  • INTS $0.19
  • PHH $0.41
  • 52 Week High
  • INTS $4.18
  • PHH $41.49
  • Technical
  • Relative Strength Index (RSI)
  • INTS 36.68
  • PHH 30.72
  • Support Level
  • INTS $0.22
  • PHH $0.44
  • Resistance Level
  • INTS $0.25
  • PHH $0.55
  • Average True Range (ATR)
  • INTS 0.02
  • PHH 0.05
  • MACD
  • INTS -0.00
  • PHH 0.23
  • Stochastic Oscillator
  • INTS 29.27
  • PHH 51.01

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

About PHH Park Ha Biological Technology Co. Ltd. Ordinary Shares

Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.

Share on Social Networks: